

Ledyenska Ballesteros, MPAS, PA-C



2023 Advisory Board for Novo Nordisk



All relevant financial relationships have been mitigated.

#### Disclosures:

#### Identify

#### Discuss

#### Recognize

#### Recommend

Identify common challenges/factors in obesity management.


Discuss steps to treat obesity in the geriatric population. Recognize
limitations with
obesity
management in
the geriatric
population.

Recommend realistic patientcentered options for individualized treatment plans.

#### Learning Objectives:

#### **Majority of Americans are Overweight or Have Obesity**

Percentage of American Adults with BMI>30 (Percentage of Americans Who Have Obesity)<sup>1</sup>




Percentage of Americans Over Age 20 Who Are Overweight or Have Obesity<sup>2</sup>



References: 1. https://www.cdc.gov/nchs/about/factsheets/factsheet\_nhanes.htm. 2. https://www.cdc.gov/nchs/fastats/obesity-overweight.htm

#### **Adult Prevalence of Obesity by Age Groups**



In 2020, 41.5% of Americans over the age of 60 suffered with obesity.

<sup>\* &</sup>quot;US population by year, race, age, ethnicity, & more". USAFacts. May 18, 2023. Retrieved June 3, 2023.

<sup>\*</sup> https://www.investopedia.com/financial-edge/0912/which-income-class-are-you.aspx

#### Today's Numbers




In 2020, the US Census Bureau confirmed that about 1 in 6 people in the United States were 65 and over.





According to the Census, the number of Americans 65yo+ will increase from 58 million (17% of the population) in 2022 to 73 million (21% of the population) by 2030.



<sup>\* &</sup>quot;US population by year, race, age, ethnicity, & more". USAFacts. May 18, 2023. Retrieved June 3, 2023.

<sup>\*</sup> https://www.investopedia.com/financial-edge/0912/which-income-class-are-you.aspx

#### Medicare

#### **Enrollments**

 Almost all Americans 65 and up are automatically entitled to health insurance benefits under the Medicare program. Today over 95 percent of the nation's elderly have Medicare coverage.



#### Costs

- In 2022, Medicare cost \$747
   billion about 12 percent of total federal government spending.
- Medicare was the second largest program in the federal budget last year, after Social Security.

#### 10 Common Chronic Conditions **for Adults 65+**(ln 2018)



Hypertension (High Blood Pressure)

60%



Chronic Kidney Disease

25%



High Cholesterol

51%



**Arthritis** 35%



Ischemic / Coronary Heart Disease

29%



Diabetes

27%





Heart Failure

15%



Depression

16%



Alzheimer's Disease and Dementia

12%



Chronic Obstructive Pulmonary Disease

11%

•In 2018, research by the National Counsel on Aging found that nearly 95% of adults 60 and older have at least one chronic condition, while nearly 80% have two or more.

Did you notice which diagnosis is missing?

Source: Centers for Medicare & Medicaid Services, Chronic Conditions Prevalence State/County Table: All Fee-for-Service Beneficiaries,



#### Obesity and its Co-Morbidities



#### **Heart Disease:**

 Increased weight can cause elevated blood pressure, high cholesterol and stress on heart.

#### **Diabetes:**

 Obesity leads to insulin resistance which can cause sugar levels to remain chronically elevated.


#### Cancer:

 40% of cancers are linked to obesity, including breast, colon, and ovarian cancer. (Healthcentral)

#### **Premature Death:**

 2.8 million people die yearly due to obesity. (WHO)

# What Prevents Clinicians from Addressing Obesity in the Geriatric Population?



## Findings from the 2021 OBSERVE Survey (by Eli Lilly Pharmaceuticals)

67%1

 Providers surveyed think people with obesity should be "required to demonstrate motivation to make lifestyle changes before medical treatment is offered."

58%1,2

• Providers surveyed think obesity was mainly due to lifestyle choices.

67%1

 Participants living with obesity shared that they do not categorize their weight as "obese."

64%2

 Participants were unaware that prescription AOMs could help manage weight

<sup>1.</sup> Obesity Medicine Association. Accessed September 21, 2023. https://obesitymedicine.org/the-observe-study-insights-into-anti-obesity-medication-perceptions-and-barriers/ 2. Eli Lilly and Co. Accessed September 21, 2023. https://www.lilly.com/news/stories/identifying-drivers-barriers-antiobesity-medicine-use

Overweight is defined as a BMI at or above 25.

Obesity is defined as a BMI at or above 30.

Obesity is Excessive Fat Accumulation presenting a risk to one's health.

## How Do We DEFINE Obesity in the Geriatric Population?

Lifestyle Modifications

Prescribed Nutrition

Pharmacotherapy

Bariatric Surgery

# How Do We MANAGE Obesity in the Geriatric Population?

## Managing Obesity in the Primary Care Office THE INITIAL VISIT:

#### **GATHER**

- Detailed Medical History
- Detailed Physical Exam
- Weight History (Flowsheet/Graph)

#### **PERFORM**

- EKG
- Labs:
  - Routine: CMP, Lipid, HgbA1c, TSH
  - Specialized: TSH, Insulin, Hormones, Food Allergens

#### **TREAT**

- Lifestyle Modifications
- Co-Morbidities
- Adjust Medications
- Prescribe Anti-Obesity Medications
- Refer to specialists

## Managing Obesity in the Primary Care Office THE FOLLOW-UP VISIT:

#### **GATHER**

- Changes since last visits
  - Food Journal
  - Physical Activity Logs
  - Medication Adjustments
  - Comorbidities

#### **PERFORM**

- Physical Exam
- Labs
- Progress Reports
- Lifestyle Modifications

#### **TREAT**

- Co-Morbidities
- Adjust Medications
- Prescribe Anti-Obesity
   Medications
- Discuss Progress and Realistic Goals
- Address Factors

# Challenges/ Factors in Obesity Management:



**Behavioral** 



**Biological** 



**Environmental/Social** 



**Medical/Pharmaceutical** 



**Psychological** 

### BEHAVIORAL FACTORS

Are patients partially responsible?

Behavioral Factors

Unhealthy Diet

Sedentary Lifestyle Sleep Deprivation

# Anti-Obesity Diets



**Keto Diet** 



**Paleo Diet** 



**Intermittent Fasting** 



**Mediterranean Diet** 



**Low Carb Diet** 



**Raw Food Diet** 



**DASH Diet** 



And the List Goes On...

# The BEST weight loss diet is the one the patient can use long term.



**Meet Nutritional Needs** 



Is High in Nutrient-Dense Foods



Promotes a Good Relationship with Foods



**Gives Patients Energy** 



**Keeps Patients Full and Happy** 



Easy To Follow and Maintain

#### AGE

- Consider dental restrictions such as dentures.
- Remember dietary restrictions:
  - ➤ Malnourishment in low calorie diets
  - Grapefruit or green vegetables vs. meds and warfarin

#### CULTURE

- Remember belief that food is an expression of love.
- "Don't waste food..."
- Educate on different ways to cook favorite foods.

#### **ECONOMY**

- Remember food deserts.
- Help research frozen foods and canned foods.
  - Explain nutrition labels.
- Explore WIC, Food banks, and processed foods


#### Manages Weight Increases Muscle **Boosts** Strength Energy and Endurance **Physical Activity Benefits** Reduces **Promotes** Better Heart Sleep Disease **Improves** Mood and Mental Health

# When it comes to weight loss and "exercise"...

- Physical Activity vs. Exercise
  - Words Matter!
- Remember the 80/20 Rule.
- Physical activity provides multiple health benefits, besides weight loss.
- Physical activity builds lean muscle mass, often lost during weight loss.
  - Muscle Atrophy
  - Sarcopenia

#### Sarcopenia

- · CAUSE:
  - Ages 60yo +
  - Atrophy (Decrease in size) and amount of muscle fiber
- SX:
  - Weakness
  - Slow movement
  - Poor balance/falls
  - Muscle atrophy
- DX:
  - Muscle strength tests
  - SARCF Questions:
    - <u>S</u>trength
    - Assistance with walking
    - Rising from chair
    - <u>Climbing stairs</u>
    - <u>F</u>alls
- TX:
  - Physical Activity
  - Healthy Diet with Increased Protein



https://medcraveonline.com/EMIJ/challenges-in-treatment-of-obesity-in-the-elderly.html#fig3

#### AGE

- Fall precautions are vital!
- Try YouTube videos & Sit, Be Fit for those with limited mobility.
- Find local senior centers to help with social interaction.
- Sarcopenia is a loss of skeletal mass/function due to weight loss. Do the SARC-F questionnaire.


#### **CULTURE**

- Focus on group-oriented culture: involve the family/ children.
- Consider incorporating in daily lifestyle:
  - using staircase at work or exercising during commercials.
- Is there a lack of transportation?

#### **ECONOMY**

- Encourage free videos/downloads or free FitOn app.
- Try walking at Wal-Mart, Costco, Mall, etc. before shopping.
- Use the outdoors, but keep in mind safety and weather.
- Purchase cheap weights at 5 Below or pedometer at Walmart.
- Fill water bottles with rice/beans or try alternatives to gyms.

#### Sleep Deprivation and Obesity



#### AGE

- Think urinary incontinence or nocturia.
- Test for OSA with STOP-Bang questionnaire.
- Do they suffer from dementia/anxiety or medically induced insomnia?

#### **CULTURE**

- Are they retired or working late/early?
- Consider multiple generations living at home and their schedules at night.

#### **ECONOMY**

- Is home security/safety an issue?
- Urban neighborhoods and noise complaints.

# ENVIRONMENTAL FACTORS

What influences patients' behavioral choices?

#### **Environmental Factors Influencing Obesity Management:**

#### **Family**

- Family Meals and Celebrations
- Household Influences: Who Plans/Buys/Cooks/Serves?

#### Relationships

- Marital Status and Children
- Work Environment

#### Heritage

- Celebrations
- Traditions

#### Religion

- Kosher Foods, Prohibited Foods
- Fasting and Religious Restrictions

#### Geography

- Access to Foods/Food Deserts and Seasonal Foods
- Rural v. Urban, Climate/Weather, Crime, Transportation

#### **Environmental Factors Influencing Obesity Management:**

#### **Education**

- Literacy
- Language Barriers

#### Socioeconomic

- SNAP, WIC, Food Banks
- Meals on Wheels, Assisted Living

#### Health

- Comorbidities: DMII, Hyperlipidemia, Anemia
- Medications

#### **Stages of Life**

- Nutritional Needs
- Independent vs. Dependent on Others

#### **Personal Beliefs**

- Exercise Avoidance
- Food Preferences

#### AGE

- Use paper food journals instead of phone apps.
- Consider how to change lifelong habits.
- Set goals by moving down obesity stages instead of ideal weight due to malnutrition and muscle loss/atrophy.

#### **CULTURE**

- Remember: Family/friend recommendations are valued.
- Evaluate traditional roles in families and how they influence treatment.
- Are they bilingual or Spanish speaking only?
  - Limited resources available. (Microsoft translator)

#### **ECONOMY**

- Consider lack of formal education.
  - Illiterate or grade level reading/understanding pose challenge.
  - Take photos of foods for journal.

#### Small Changes in the Real World

**Portion Control** 

Removing one Favorite Item per day/week

Adding one New Item per day/week Replacing Food/Drink w/ Similar Option

Increasing Sleep by 30 minutes

10 minutes+ Physical Activity Adding 200-500 steps per day

Setting Alarms as Reminders

Rearranging Schedules

Adjusting Medications and Dosages



The "Butterfly Effect" is the idea that small changes can have large impacts on a complex system.

# PSYCHOLOGICAL FACTORS

Is there more than "emotional eating?"



#### **Eating Disorders**

Anorexia

Bulimia

Binge Eating Disorder

Night Eating Disorder



#### **Situational Stressors**

Conflicts in Relationships

Life Events

Acute vs. Chronic Stressors

Weight Bias and Self-Esteem



#### **Emotional Coping**

Depression and Bipolar Disorders

**Anxiety and Social Anxiety** 

PTSD, Trauma, and/or Abuse

Emotional Hunger vs. Physical Hunger

#### Psychological Factors:

#### AGE

- Test for possible dementia: MMSE.
- Add PHQ-9 and GAD-7 screening tests.

#### CULTURE

- Remember the stigma of anti-depressants and therapy.
  - Consider telehealth visits.
- Ask about situational and emotional stressors.

#### **ECONOMY**

- Expensive psychotherapy sessions without insurance coverage are an issue.
  - ➤ Are there even any availabilities? Is there a wait list?
  - Consider <u>www.psychologytoday.com</u>, church or free local resources.

### BIOLOGICAL FACTORS

Is it all in the genes?

Biological Factors:

 Maternal Influences

> For Mother

> For Child

• Predisposition

Gender

Metabolic

Thermogenesis

Menopause/Age

Insulin Resistance

Height Respo

Heightened Hunger Response

Delayed Satiety

 Endocrinological Disorders Physical


Genetic

ChronicInflammation

**Physical Disabilities** 

 Food Sensitivities/ Gut Microbes

#### Obesity Impacts Nearly Every Organ System




# Physical Exam in **Patients** with Obesity

(useful when billing)

SYSTEM	FINDINGS	COMORBIDITY CONCERNS
Vitals	Elevated Blood Pressure	HTN, Stroke Risk
Skin	Acanthosis Nigricans	DMII
	Hirsutism, Acne	PCOS
	Irritation, Inflammation, Rashes	Cardiac or Rheumatoid Disorders
Eyes	Bulging Eyes	Graves Disease
Throat	Tonsillar Hypertrophy	Obstructive Sleep Apnea
Neck	Goiter	Hypothyroidism
	Enlarged	Obstrutive Sleep Apnea
Chest	Wheezing	Asthma, OSA,
	Excess Chest Fat	Gynecomastia
Abdomen	Tenderness	GERD, Cholelithiasis, Fatty Liver
	Hepatomegaly	Nonalcoholic Fatty Liver Disease
	Excess Visceral Fat	Central Obesity
Reproductive	Apparent Micropenis	Excess Fat
	Irregular Periods	PCOS
Extremities	Abnormal Gait	Arthritis
	Muscle Atrophy	Sarcopenia
	Venous Stasis/Varicose Veins	Circulation D/O

# Metabolic Syndrome: 3 or more traits (NIH Classification)



# PHARMACOLOGICAL FACTORS

Are we prescribing obesogenic medications?

# Obesogenic Medications

Medical Specialty	Drug Class	Associated with Weight GAIN	Alternative/ Weight NEUTRAL	Alternative/ Weight LOSS
Psychiatry	Anti-depressants	<ul> <li>TCAs (Amitriptyline, nortiptyline)</li> <li>SSRIs (paroxetine, escitalopram)</li> </ul>	• SSRIs (fluoxetine, sertraline)	• Bupropion
	Anti-psychotics	<ul><li>MAOIs</li><li>Lithium</li><li>Quetiapine, Risperidone</li></ul>		• Aripiprazole
Neurology	Anti-epileptics	<ul><li>Gabapentin,</li><li>Pregabalin</li><li>Valproate</li></ul>		<ul><li>Topiramate</li><li>Zonisamide</li><li>Lamotrigine</li></ul>

# Obesogenic Medications

Medical Specialty	Drug Class	Associated with Weight GAIN	Alternative/Weight NEUTRAL	Alternative/Weight LOSS
Endocrinology	Anti-Diabetic Medications	<ul><li>Sulfonylureas</li><li>Thiazolidinediones</li><li>Insulins</li></ul>	<ul> <li>DPP4 inhibitors</li> <li>Alpha-glucosidase inhibitors</li> <li>Bile acid sequestrants</li> </ul>	<ul><li>GLP-1s and GIPs</li><li>SGLT2 inhibitors</li><li>Metformin</li></ul>
	Steroids	• Corticosteroids	<ul> <li>Low-dose corticosteroids</li> </ul>	
Ob/Gyn	Contraceptives	<ul><li>Depo-provera</li><li>Progesterone</li></ul>	• OCPs	<ul><li>Copper IUD</li><li>Low Dose OCPs</li></ul>

# Obesogenic Medications

Medical Specialty	Drug Class	Associated with Weight GAIN	Alternative/Weight NEUTRAL	Alternative/Weight LOSS
Cardiology	Hypertensive Medications	<ul> <li>Alpha-adrenergic blockers</li> <li>Beta Blockers (Metoprolol)</li> </ul>	<ul> <li>ACE Inhibitors</li> <li>Angiotensin         receptor blockers</li> <li>Beta-adrenergic         blockers (carvedilol)</li> <li>Calcium Channel         Blockers</li> <li>Thiazides</li> </ul>	• Furosemide
General	Antihistamines	Diphenhydramine	Short-term use	

### A Timeline of FDA Anti-Obesity Medication Approval

1933

Dinitrophenol (DNP) is approved

1956

Phenmetrazine is approved

1947

Methamphetamine is approved

1959

Phendimetrazine, diethylpropion, & phentermine are approved

1960

Benzphetamine & phenylpropanolamine are approved

1961

"Rainbow pills" are approved

1973

Fenfluramine is approved

1996

Dexfenfluramine is approved

1997

Sibutramine is approved

1999

Orlistat is approved

2012

Lorcaserin & phentermine/ topiramate is approved

2014

Liraglutide & naltrexone/bupropion are approved

2021

Semaglutide is approved

1968

pressure, death

"Rainbow pills" are withdrawn

Side effects include: insomnia, palpitations, anxiety, increased heart rate & blood

DNP is withdrawn

1938

Side effects include: hyperthermia, tachycardia, fever, tachypnoea, death

1979

Methamphetamine is withdrawn

Side effects include: high risk for abusiveness & addiction

1997

Fenfluramine &

dexfenfluramine are withdrawn

Side effects include: cardiac valvular insufficiency & pulmonary hypertension

2000

Phenylpropanolamine is withdrawn

Side effects include: hemorrhagic stroke

2020

Lorcaserin is withdrawn

Side effects include: depression, suicidal ideation, palpitations, gastrointestinal upset, increased cancer risk

2010

Sibutramine is withdrawn

Side effects include: non-fatal myocardial infarction & stroke (with pre-existing CVD)



# A Closer Look into the Approved AOMs:

#### **Orlistat**

- PROS: Prohibits 33% Fat Absorption
- CONS: Anal leakage

#### **Phentermine**

(also Phendimetrazine and Diethylpropion)

- PROS: Increased Energy and Decreased Appetite
- CONS: Elevated BP and Heart Rate

#### Phentermine/Topiramate ER

- PROS: Increased Energy and Faster Satiety
- CONS: Can cause Drowsiness/Brain Fog/Tingling

#### Naltraxone/Bupropion ER

- PROS: Stop Cravings
- CONS: Possible psychosis/suicidal ideation

#### Liraglutide

- PROS: Can use Victoza instead, initial ~5-8% weight loss
- CONS: Insurance coverage, gallstones, kidney stones, gastroparesis

#### Semaglutide

- PROS: Can use Ozempic, once a week, 12yo+, almost 20% weight loss
- CONS: Insurance coverage, Ozempic approved for DMII only, gallstones, kidney stones... <u>AVAILABILITY DUE TO SHORTAGE</u>

### **BREAKING NEWS...**

- NOVEMBER 8, 2023: Tirzepatide (GLP1/GIP) was approved as the anti-obesity medication: Zepbound.
- One month supply costs \$1090 (cash pay) and is now available as of 2024.
- \$25 coupon cards are available on the manufacturer's website.
- Weight loss exceeds Semaglutide, averaging at 22.5%.



# **MORE BREAKING NEWS...**

#### MARCH 2024:

- Under the CMS' guidelines, Wegovy can be prescribed to patients with overweight/obesity that have heart disease.
- Medicare will not cover Wegovy if it is only prescribed for weight loss.
- Keep in mind deductibles and copays.

Medicare Part D Coverage for Wegovy Obesity +

**Doctor submits** documentation to indicate why other medications are not clinically appropriate to treat condition. Prior Myocardial Infarction **Prior Stroke** (Ischemic or Hemorrhagic) Intermittent Claudication with Ankle Brachial Index < 0.85

Peripheral Arterial Revascularization Procedure

Peripheral Arterial

Disease

Failed Attempt

with Other

Medications for

**Medical Condition** 

Cardiovascular

Disease


Amputation due to Atherosclerotic Disease

# **Key Findings:**

Participants (327) regained two-thirds of their previous weight loss (11.6%) a year (52 weeks) after discontinuing semaglutide 2.4mg.

#### STEP-1 Trial Extension - Semaglutide 2.4 mg

Figure 1 - Panel A (adapted from Wilding et al., DOM, 2022)



https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542252/

https://pubmed.ncbi.nlm.nih.gov/35441470/

#### Proportion of Patients by Weight Change After Stopping Semaglutide



11 20/27 Patients 110pot tion of 1 attents by Weight Change Fitter Stopping Semagnature, 202 is epictedeal of

Figure 1. The proportion of patients by amount of weight regained or lost after stopping semaglutide.

Similarly, we studied 17,733 patients prescribed liraglutide who achieved a weight loss of at least five pounds while on the medication. Among this group, 18.7% experienced complete weight regain or surpassed their initial weight. However, 55.7% of these patients either remained around the weight they were at when stopping the medication or continued to lose additional weight.

# **Key Findings:**

- 56% of patients maintain or continue with weight loss a year after discontinuing semaglutide or liraglutide.
- However, 18.7% of liraglutide users and 17.7% of semaglutide users regained all the weight they had lost or more.

# 3<sup>rd</sup> and 4<sup>th</sup> Generation Anti-Obesity Medications:

Medication	Company	MOA	% Weight Loss	Current Status
Retatrutide	Eli Lilly	GLP-1/ GIP/ Glucagon (weekly injection)	25%	Phase 2 Trial
Oral Semaglutide 50mg	Novo Nordisk	GLP-1 (oral tablet)	20%	OASIS Trial: Phase 3
CagriSema (cagrilintide and semaglutide)	Novo Nordisk	GLP-1/Amylin (weekly injection)	<b>15%</b> (in 20 weeks)	Phase 3 Trial
Ecnoglutide	Sciwind Biosciences	GLP-1 (weekly injection)	14%	Phase 2 Trial (Oral- Phase 1)
Orforglipron	Eli Lilly	GLP-1 (oral tablet)	15%	Phase 2 Trial (Small molecule and significantly cheaper)
Danuglipron	Pfizer	GLP-1 (oral tablet)	<b>13%</b> (in 32 weeks)	<b>Phase 2 Trial</b> (Twice a day version was d/c in 12/2023.)

### AGE

- Adjust current medications first, if possible.
  - ➤ Inform specialists.
- Are there interactions with current meds or disorders?
- Assess polypharmacy costs.


### **CULTURE**


- Address stigma behind certain medications like Metformin.
- Explain the difference in GLP1 injections and insulin.


### **ECONOMY**

- Confirm if medication is available in generics.
- Consider 30 days vs. 90 days scripts.
- Consider GoodRX, SingleCare, and assistance programs.

# **Bariatric Treatment**







https://www.vidawellnessandbeauty.com/weight-loss-surgery/tijuana-why-is-it-the-leading-bariatric-surgery/

https://my.clevelandclinic.org/health/treatments/17285-bariatric-obesity-surgery

//www.uclahealth.org/Medical-services/gastro/ies/patient-resources/endoscopic-treatment-obesity/endoscopic-suturing-weight-gain-after-bariatric-surgery

Surgeries are non-reversible, except for gastric banding (lap-band) and the new gastric balloon.

A person must have a BMI over 34 for most insurances to cover.

The gastric sleeve is currently the most common option.

FORTUNATELY, <u>90% of bariatric patients lost</u> about 50% of weight within 1<sup>st</sup> two years.

40% maintained at least 30% weight loss after 12 years.

UNFORTUNATELY, <u>25% regain all their lost</u> weight after 10 years.

### AGE

- Consider pre-op medical and cardiac clearances.
- Remember age restrictions:
  - ➤ Not recommended over 70 yo.

### **CULTURE**


- Consider the stigma "easy way out"
  - > Family disapproval
- Many perceive it as cosmetic & not medically necessary.
- Many fear risks and medical complications

### ECONOMY

- Lap band costs: \$14,500 average
- Sleeve gastrectomy costs: \$14,900 average
- Bypass costs: \$23,000 average

BC

#### **Recommending a Patient-Centered Obesity Treatment Plan:**



# Ledyenska Baez Ballesteros, MPAS, PA-C

Email: Ledyenska.baez@gonzaba.com

# PAs in Obesity Medicine

www.PAsinObesityMedicine.org

Email: PAsinObesityMedicine@gmail.com

#### MEET AND GREET LUNCHEON

12p at the Scot Cotton Room

On the 2<sup>nd</sup> Floor of the Marriott Marquis Houston

- Obesity Algorithm. 2017-2018. Obesity Medicine Association
- > Saunders KH, Shukla AP, Igel LI, Aronne LJ. Obesity: When to consider medication. The Journal of Family Practice. 2017: 66:608-615.
- ➤ Diet, Drugs, Devices and Surgery for Weight Management. The Medical Letter, June 4 2018:60 (1548).
- Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA, 2016: 315(22):2424-2434.
- https://www.obesitycareweek.org/resources-for-healthcare-professionals/
- ➤ Vallis M, Piccinini--Vallis H, Sharma A, Freedhoff Y. Modified 5 As Minimal intervention for obesity counseling in primary care. Canadian Family Physician. 2013;59(1):27—31
- Kyrou I, Randeva HS, Tsigos C, et al. Clinical Problems Caused by Obesity. [Updated 2018 Jan 11]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: <a href="https://www.ncbi.nlm.nih.gov/books/NBK278973/">https://www.ncbi.nlm.nih.gov/books/NBK278973/</a>

- Kim TN. Barriers to Obesity Management: Patient and Physician Factors. J Obes Metab Syndr. 2020 Dec 30;29(4):244-247. doi: 10.7570/jomes20124. PMID: 33342768; PMCID: PMC7789016.
- National Health and Nutrition Examination Survey 2017—March 2020 Prepandemic Data Files Development of Files and Prevalence Estimates for Selected Health Outcomes. Personal Author(s): Stierman, Bryan; Afful, Joseph; Carroll, Margaret D.; Chen, Te-Ching; Davy, Orlando; Fink, Steven; Fryar, Cheryl D.; Gu, Qiuping; Hales, Craig M.; Hughes, Jeffery P.; Ostchega, Yechiam; Storandt, Renee J.; Akinbami, Lara J.; Corporate Authors(s): National Center for Health Statistics (U.S.) Published Date: 06/14/2021 Series: NHSR No. 158 Source: National Health Statistics Reports URL: https://stacks.cdc.gov/view/cdc/106273
- ➤ Malenfant JH, Batsis JA. Obesity in the geriatric population a global health perspective. Journal of Global Health Reports. 2019;3:e2019045. doi:10.29392/joghr.3.e2019045
- https://www.ncbi.nlm.nih.gov/books/NBK278973/
- https://www.advisory.com/blog/2022/12/weight-loss-drugs
- https://www.pgpf.org/budget-basics/medicare#:~:text=In%2ofiscal%2oyear%2o2o22%2C%2othe,last%2oyear%2C%2oafter%2oSocial%2oSecurity.

- > Gunther S, Guo F, Sinfield P, Rogers S, Baker R. Barriers and enablers to managing obesity in general practice: A practical approach for use in implementation activities. Quality in primary care. 2012;20(2):93-103. Accessed 3 June 2014.
- https://www.weforum.org/agenda/2018/05/we-need-to-change-the-narrative-around-obesity-heres-why/
- https://www.ncbi.nlm.nih.gov/books/NBK532533/
- https://obesitymedicine.org/
- CDC.gov Healthy Weight: Assessing Your Weight: BMI About Adult BMI. DNPAO. CDC. 2011
- Hruby A, Hu FB. The Epidemiology of Obesity: A Big Picture. Pharmacoeconomics. 2015 Jul;33(7):673-89. doi: 10.1007/s40273-014-0243- x. PMID: 25471927; PMCID: PMC4859313.
- Michigan Medicine University of Michigan. "What will it take to transform obesity care for all?." ScienceDaily. ScienceDaily, 31 May 2022. .
- https://www.nhlbi.nih.gov/health/overweight-and-obesity
- > Atkins, J., & Wannamathee, S. (2020). Sarcopenic obesity in ageing: Cardiovascular outcomes and mortality. *British Journal of Nutrition*, 124(10), 1102-1113. doi:10.1017/S0007114520002172
- ➤ 1. Obesity Medicine Association. Accessed September 21, 2023. https://obesitymedicine.org/the-observe-study-insights-into-anti-obesity-medication-perceptions-and-barriers/ 2. Eli Lilly and Co. Accessed September 21, 2023. https://www.lilly.com/news/stories/identifying-drivers-barriers-antiobesity-medicine-use
- https://insidescientific.com/recent-advances-in-anti-obesity-pharmacological-research/

- https://gastro.org/wp-content/uploads/2022/10/COM22-017-Obesity-Guideline-Chart-Graphic-11-FB.jpg
- https://www.advisory.com/blog/2022/12/weight-loss-drugs
- > https://insidescientific.com/recent-advances-in-anti-obesity-pharmacological-research/
- https://www.healthline.com/health-news/bias-and-outdated-views-are-keeping-many-doctors-from-treating-obesity-effectively#What-the-data-highlights-about-attitudes-toward-obesity
- https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/sarcopenic-obesity-in-ageing-cardiovascular-outcomes-and-mortality/7BD2F6B4E1365590D504173D2549A724
- https://my.clevelandclinic.org/health/diseases/23167-sarcopenia#:~:text=Sarcopenia%20is%20the%20age%2Drelated,by%20the%20natural%20aging%20process.
- Gunther S, et al. Qual Prim Care. 2012;20(2):93-103. Accessed September 21, 2023. <a href="https://pubmed.ncbi.nlm.nih.gov/22824562/">https://pubmed.ncbi.nlm.nih.gov/22824562/</a>
- https://my.clevelandclinic.org/health/treatments/17285-bariatric-obesity-surgery
- https://www.nutritionrdn.com/weight-loss-surgery-in-totowa
- > //www.uclahealth.org/medical-services/gastro/ies/patient-resources/endoscopic-treatmentobesity/endoscopic-suturing-weight-gain-after-bariatric-surgery
- https://acl.gov/sites/default/files/Aging%20and%20Disability%20in%20America/2020ProfileOlderAmericans.F inal .pdf